This is a recent publication by IVI entitled “Prioritizing attributes to better define and measure innovation in health technology assessment“. The expert roundtable convened by the IVI examined not only whether there was consensus on how to implement the elements of value (“method readiness”), but whether they had reliable data to estimate the elements of value in practice (“data quality”). IVI Expert Panel Found the following:
Accessibility, affordability, optimized access to care, and clinical and economic burden were categorized as attributes with good data and methods, but the use of quality data and validated methods was inconsistent across stakeholders and diseases.
Patient well-being and improved health outcomes are attributes judged with a number of emerging data sources and methodologies. Family spillover 5, reduced patient burden and ease of treatment were identified as attributes with some emerging data sources but lacking methods.
Family spillover occurs when a disease and its management affect not only the person diagnosed with the disease, but also family members who may or may not directly provide care. Impact on wider society, real option value, productivity, understanding the root causes of disease and societal burden are attributes judged to be established methods but requiring additional data collection efforts when applying these methods.
Finally, scientific spillover8 is considered a property of lack of established data and methods.
You can read the full value blueprint here.
